专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07323311B2 Methods of obtaining a specific binding member that binds eotaxin 有权
标题翻译：获得结合嗜酸性粒细胞趋化因子的特异性结合成员的方法
公开(公告)号：US07323311B2
公开(公告)日：2008-01-29
申请号：US10220418
申请日：2001-03-02
申请人： Tristan John Vaughan , Alison Jane Wilton , Stephen Smith , Sarah Helen Main
发明人： Tristan John Vaughan , Alison Jane Wilton , Stephen Smith , Sarah Helen Main
IPC分类号： G01N33/53 , C12P21/06 , C12P21/04
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2319/00 , C12P21/00
摘要： Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralise eotaxin-1 activity. The antibodies VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT 213. One or more complementary determing regions (CDRs) of the CAT-212/-213 VH and/or VL domains, especially VH CRD3 in other antibody framework regions. Compositions containing specific binding members, and their use in methods of inhibiting or neutralising eotaxin, including methods of treatment of the human or animal body by therapy.
摘要翻译：针对嗜酸细胞活化趋化因子-1的特异性结合成员，特别是针对人类嗜酸细胞活化趋化因子-1的人抗体和抗体片段，特别是中和嗜酸性粒细胞趋化因子-1活性的那些。本文称为CAT-212和本文称为CAT 213的IgG4抗体的scFv片段的抗体VH和/或VL结构域.CAT-212 / -213VH和/或VL结构域的一个或多个互补的确定区（CDR），特别是VH CRD3在其他抗体框架区域。含有特异性结合成员的组合物及其在抑制或中和嗜酸性粒细胞趋化因子的方法中的用途，包括通过治疗来治疗人或动物体的方法。

2. 发明授权

US08067564B2 Methods of obtaining a specific binding member that binds eotaxin 有权
标题翻译：获得结合嗜酸性粒细胞趋化因子的特异性结合成员的方法
公开(公告)号：US08067564B2
公开(公告)日：2011-11-29
申请号：US11958210
申请日：2007-12-17
申请人： Tristan John Vaughan , Alison Jane Wilton , Stephen Smith , Sarah Helen Main
发明人： Tristan John Vaughan , Alison Jane Wilton , Stephen Smith , Sarah Helen Main
IPC分类号： C07H21/04 , C12N5/00 , C07K17/00
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2319/00 , C12P21/00
摘要： Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralize eotaxin-1 activity. The antibodies VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT 213. One or more complementary determining regions (CDRs) of the CAT-212/-213 VH and/or VL domains, especially VH CRD3 in other antibody framework regions. Compositions containing specific binding members, and their use in methods of inhibiting or neutralizing eotaxin, including methods of treatment of the human or animal body by therapy.
摘要翻译：针对嗜酸细胞活化趋化因子-1的特异性结合成员，特别是针对人类嗜酸细胞活化趋化因子-1的人抗体和抗体片段，特别是中和嗜酸性粒细胞趋化因子-1活性的那些。本文称为CAT-212和本文称为CAT 213的IgG4抗体的scFv片段的抗体V H和/或VL结构域.CAT-212 / -213VV和/或VL结构域的一个或多个互补决定区（CDR），特别是VH CRD3在其他抗体框架区域。含有特异性结合成员的组合物及其在抑制或中和嗜酸性粒细胞趋化因子的方法中的用途，包括通过治疗来治疗人或动物体的方法。

3. 发明授权

US06946546B2 Human antibodies against eotaxin 有权
标题翻译：抗嗜酸性粒细胞趋化因子的人抗体
公开(公告)号：US06946546B2
公开(公告)日：2005-09-20
申请号：US09798058
申请日：2001-03-02
申请人： Tristan John Vaughan , Alison Jane Wilton , Stephen Smith , Sarah Helen Main
发明人： Tristan John Vaughan , Alison Jane Wilton , Stephen Smith , Sarah Helen Main
IPC分类号： C07K16/24 , C07K16/00 , C07K16/28
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/21 , C07K2317/622
摘要： Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralize eotaxin-1 activity. The antibody VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT-213. One or more complementarity determining regions (CDRs) of the CAT-212/-213 VH and/or VL domains, especially VH CDR3 in other antibody framework regions. Compositions containing specific binding members, and their use in methods of inhibiting or neutralizing eotaxin, including methods of treatment of the human or animal body by therapy.
摘要翻译：针对嗜酸细胞活化趋化因子-1的特异性结合成员，特别是针对人类嗜酸细胞活化趋化因子-1的人抗体和抗体片段，特别是中和嗜酸性粒细胞趋化因子-1活性的那些。本文称为CAT-212和本文称为CAT-213的IgG4抗体的scFv片段的抗体VH和/或VL结构域。 CAT-212 / -213VV和/或VL结构域的一个或多个互补决定区（CDR），特别是其他抗体框架区中的VH CDR3。含有特异性结合成员的组合物及其在抑制或中和嗜酸性粒细胞趋化因子的方法中的用途，包括通过治疗来治疗人或动物体的方法。

4. 发明授权

US06342588B1 Labelling and selection of molecules 有权
标题翻译：分子标记和选择
公开(公告)号：US06342588B1
公开(公告)日：2002-01-29
申请号：US09375314
申请日：1999-08-16
申请人： Jane Katharine Osbourn , Elaine Joy Derbyshire , John Gerald McCafferty , Tristan John Vaughan , Kevin Stuart Johnson
发明人： Jane Katharine Osbourn , Elaine Joy Derbyshire , John Gerald McCafferty , Tristan John Vaughan , Kevin Stuart Johnson
IPC分类号： G01N33537
CPC分类号： G01N33/532 , A61K38/00 , C07K1/36 , C07K14/523 , C07K14/70542 , C07K14/70596 , C07K14/82 , C07K16/00 , C07K16/065 , C07K16/22 , C07K16/2854 , C07K16/2866 , C07K16/2896 , C07K16/3007 , C07K16/32 , C07K16/4266 , C07K2317/34 , C07K2317/622 , C12N9/16 , G01N33/535
摘要： A method of labelling molecules which includes providing in a common medium a label molecule, a marker ligand able to bind a member of a specific binding pair, such as an antigen, a sbp member, an enzyme able to catalyse binding of the label molecule to other molecules, the enzyme being associated with the marker ligand; causing or allowing binding of the marker ligand to the sbp member; and causing or allowing binding of the label molecule to other molecules in the vicinity of the marker ligand bound to the sbp member. The marker ligand may be an antibody or any specific binding molecule, such as a chemokine or cytokine. A complementary member of the specific binding pair may be included, e.g. an antibody, or a diverse population of such sbp members, e.g. antibodies, may be included within which those which bind the counterpart sbp member, e.g. antigen, may be labelled and subsequently isolated for manipulation and/or use. Suitable labels include biotin-tyramine with signal transfer being catalysed by hydrogen peroxidase. Cells, virus particles and other moieties may be labelled, for identification or obtention of proteins which interact or are in close proximity with a particular sbp member, or of cells of interest, or for enhancement of labelling, e.g. for cell sorting.
摘要翻译：标记分子的方法，其包括在普通培养基中提供标记分子，能够结合特异性结合对成员的标记配体，例如抗原，sbp成员，能够催化标记分子结合的酶其他分子，该酶与标记配体相关; 引起或允许标记配体与sbp构件的结合; 并引起或允许标记分子与结合到sbp构件的标记配体附近的其它分子结合。标记配体可以是抗体或任何特异性结合分子，例如趋化因子或细胞因子。可以包括特异性结合对的互补成员，例如。抗体，或这样的sbp成员的不同群体，例如。可以包括其中结合对应物sbp成员的那些抗体。抗原，可以被标记并随后分离用于操作和/或使用。合适的标记包括具有由过氧化氢酶催化的信号传递的生物素酪胺。可以标记细胞，病毒颗粒和其它部分，用于鉴定或获得与特定sbp成员或感兴趣的细胞相互作用或紧密接近的蛋白质，或用于增强标记，例如，用于细胞分选。

5. 发明授权

US06180336B2 Labelling and selection of molecules 失效
标题翻译：分子的标记和选择
公开(公告)号：US06180336B2
公开(公告)日：2001-01-30
申请号：US09098244
申请日：1998-06-17
申请人： Jane Katharine Osbourn , Elaine Joy Derbyshire , John Gerald McCafferty , Tristan John Vaughan , Kevin Stuart Johnson
发明人： Jane Katharine Osbourn , Elaine Joy Derbyshire , John Gerald McCafferty , Tristan John Vaughan , Kevin Stuart Johnson
IPC分类号： C12Q170
CPC分类号： G01N33/532 , A61K38/00 , C07K1/36 , C07K14/523 , C07K14/70542 , C07K14/70596 , C07K14/82 , C07K16/00 , C07K16/065 , C07K16/22 , C07K16/2854 , C07K16/2866 , C07K16/2896 , C07K16/3007 , C07K16/32 , C07K16/4266 , C07K2317/34 , C07K2317/622 , C12N9/16 , G01N33/535
摘要： A method of labelling molecules which includes providing in a common medium a label molecule, a marker ligand able to bind a member of a specific binding pair, such as an antigen, a sbp member, an enzyme able to catalyse binding of the label molecule to other molecules, the enzyme being associated with the marker ligand; causing or allowing binding of the marker ligand to the sbp member; and causing or allowing binding of the label molecule to other molecules in the vicinity of the marker ligand bound to the sbp member. The marker ligand may be an antibody or any specific binding molecule, such as a chemokine or cytokine. A complementary member of the specific binding pair may be included, e.g. an antibody, or a diverse population of such sbp members, e.g. antibodies, may be included within which those which bind the counterpart sbp member, e.g. antigen, may be labelled and subsequently isolated for manipulation and/or use. Suitable labels include biotin-tyramine with signal transfer being catalysed by hydrogen peroxidase. Cells, virus particles and other moieties may be labelled, for identification or obtention of proteins which interact or are in close proximity with a particular sbp member, or of cells of interest, or for enhancement of labelling, e.g. for cell sorting.
摘要翻译：标记分子的方法，其包括在普通培养基中提供标记分子，能够结合特异性结合对成员的标记配体，例如抗原，sbp成员，能够催化标记分子结合的酶其他分子，该酶与标记配体相关; 引起或允许标记配体与sbp构件的结合; 并引起或允许标记分子与结合到sbp构件的标记配体附近的其它分子结合。标记配体可以是抗体或任何特异性结合分子，例如趋化因子或细胞因子。可以包括特异性结合对的互补成员，例如。抗体，或这样的sbp成员的不同群体，例如。可以包括其中结合对应物sbp成员的那些抗体。抗原，可以被标记并随后分离用于操作和/或使用。合适的标记包括具有由过氧化氢酶催化的信号传递的生物素酪胺。可以标记细胞，病毒颗粒和其它部分，用于鉴定或获得与特定sbp成员或感兴趣的细胞相互作用或紧密接近的蛋白质，或用于增强标记，例如，用于细胞分选。

6. 发明申请

US20080182319A1 METHODS OF OBTAINING A SPECIFIC BINDING MEMBER THAT BINDS EOTAXIN 有权
标题翻译：获得特定结合成员的方法
公开(公告)号：US20080182319A1
公开(公告)日：2008-07-31
申请号：US11958210
申请日：2007-12-17
申请人： Tristan John Vaughan , Alison Jane Wilton , Stephen Smith , Sarah Helen Main
发明人： Tristan John Vaughan , Alison Jane Wilton , Stephen Smith , Sarah Helen Main
IPC分类号： C12N1/21 , C12N15/12 , C12N5/10 , C12N1/19 , C12N15/13
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2319/00 , C12P21/00
摘要： Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralise eotaxin-1 activity. The antibodies VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT 213. One or more complementary determining regions (CDRs) of the CAT-212/-213 VH and/or VL domains, especially VH CRD3 in other antibody framework regions. Compositions containing specific binding members, and their use in methods of inhibiting or neutralising eotaxin, including methods of treatment of the human or animal body by therapy.
摘要翻译：针对嗜酸细胞活化趋化因子-1的特异性结合成员，特别是针对人类嗜酸细胞活化趋化因子-1的人抗体和抗体片段，特别是中和嗜酸性粒细胞趋化因子-1活性的那些。本文称为CAT-212和本文称为CAT 213的IgG4抗体的scFv片段的抗体V H和/或VL结构域.CAT-212 / -213VV和/或VL结构域的一个或多个互补决定区（CDR），特别是VH CRD3在其他抗体框架区域。含有特异性结合成员的组合物及其在抑制或中和嗜酸性粒细胞趋化因子的方法中的用途，包括通过治疗来治疗人或动物体的方法。

7. 发明授权

US06489123B2 Labelling and selection of molecules 失效
标题翻译：分子的标记和选择
公开(公告)号：US06489123B2
公开(公告)日：2002-12-03
申请号：US09767395
申请日：2001-01-23
申请人： Jane Katharine Osbourn , Elaine Joy Derbyshire , John Gerald McCafferty , Tristan John Vaughan , Kevin Stuart Johnson
发明人： Jane Katharine Osbourn , Elaine Joy Derbyshire , John Gerald McCafferty , Tristan John Vaughan , Kevin Stuart Johnson
IPC分类号： G01N3353
CPC分类号： G01N33/532 , A61K38/00 , C07K1/36 , C07K14/523 , C07K14/70542 , C07K14/70596 , C07K14/82 , C07K16/00 , C07K16/065 , C07K16/22 , C07K16/2854 , C07K16/2866 , C07K16/2896 , C07K16/3007 , C07K16/32 , C07K16/4266 , C07K2317/34 , C07K2317/622 , C12N9/16 , G01N33/535
摘要： A method of labelling molecules which includes providing in a common medium a label molecule, a marker ligand able to bind a member of a specific binding pair, such as an antigen, a sbp member, an enzyme able to catalyze binding of the label molecule to other molecules, the enzyme being associated with the marker ligand; causing or allowing binding of the marker ligand to the sbp member; and causing or allowing binding of the label molecule to other molecules in the vicinity of the marker ligand bound to the sbp member. The marker ligand may be an antibody or any specific binding molecule, such as a chemokine or cytokine. A complementary member of the specific binding pair may be included, e.g. an antibody, or a diverse population of such sbp members, e.g. antibodies, may be included within which those which bind the counterpart sbp member, e.g. antigen, may be labelled and subsequently isolated for manipulation and/or use. Suitable labels include biotin-tyramine with signal transfer being catalysed by hydrogen peroxidase. Cells, virus particles and other moieties may be labelled, for identification or obtention of proteins which interact or are in close proximity with a particular sbp member, or of cells of interest, or for enhancement of labelling, e.g. for cell sorting.
摘要翻译：标记分子的方法，其包括在普通培养基中提供标记分子，能够结合特异性结合对成员的标记配体，例如抗原，sbp成员，能够催化标记分子结合的酶其他分子，该酶与标记配体相关; 引起或允许标记配体与sbp构件的结合; 并引起或允许标记分子与结合到sbp构件的标记配体附近的其它分子结合。标记配体可以是抗体或任何特异性结合分子，例如趋化因子或细胞因子。可以包括特异性结合对的互补成员，例如。抗体，或这样的sbp成员的不同群体，例如。可以包括其中结合对应物sbp成员的那些抗体。抗原，可以被标记并随后分离用于操作和/或使用。合适的标记包括具有由过氧化氢酶催化的信号传递的生物素酪胺。可以标记细胞，病毒颗粒和其它部分，用于鉴定或获得与特定sbp成员或感兴趣的细胞相互作用或紧密接近的蛋白质，或用于增强标记，例如，用于细胞分选。

8. 发明授权

US5994519A Labelling and selection of molecules 失效
公开(公告)号：US5994519A
公开(公告)日：1999-11-30
申请号：US889291
申请日：1997-07-08
申请人： Jane Katharine Osbourn , Elaine Joy Derbyshire , John Gerald McCafferty , Tristan John Vaughan , Kevin Stuart Johnson
发明人： Jane Katharine Osbourn , Elaine Joy Derbyshire , John Gerald McCafferty , Tristan John Vaughan , Kevin Stuart Johnson
IPC分类号： A61K38/00 , A61K49/00 , C07K1/36 , C07K14/52 , C07K14/705 , C07K14/82 , C07K16/00 , C07K16/06 , C07K16/22 , C07K16/28 , C07K16/30 , C07K16/32 , C07K16/42 , C12N9/16 , C12N15/09 , G01N33/532 , G01N33/535 , G01N33/53
CPC分类号： G01N33/532 , C07K1/36 , C07K14/523 , C07K14/70542 , C07K14/70596 , C07K14/82 , C07K16/00 , C07K16/065 , C07K16/22 , C07K16/2854 , C07K16/2866 , C07K16/2896 , C07K16/3007 , C07K16/32 , C07K16/4266 , C12N9/16 , G01N33/535 , A61K38/00 , C07K2317/34 , C07K2317/622
摘要： A method of labelling molecules which includes providing in a common medium a label molecule, a marker ligand able to bind a member of a specific binding pair, such as an antigen, a sbp member, an enzyme able to catalyse binding of the label molecule to other molecules, the enzyme being associated with the marker ligand; causing or allowing binding of the marker ligand to the sbp member; and causing or allowing binding of the label molecule to other molecules in the vicinity of the marker ligand bound to the sbp member. The marker ligand may be an antibody or any specific binding molecule, such as a chemokine or cytokine. A complementary member of the specific binding pair may be included, e.g. an antibody, or a diverse population of such sbp members, e.g. antibodies, may be included within which those which bind the counterpart sbp member, e.g. antigen, may be labelled and subsequently isolated for manipulation and/or use. Suitable labels include biotin-tyramine with signal transfer being catalysed by hydrogen peroxidase. Cells, virus particles and other moieties may be labelled, for identification or obtention of proteins which interact or are in close proximity with a particular sbp member, or of cells of interest, or for enhancement of labelling, e.g. for cell sorting.

9. 发明授权

US07368111B2 Human antibodies specific for TGFβ2 失效
标题翻译： TGFbeta2特异的人抗体
公开(公告)号：US07368111B2
公开(公告)日：2008-05-06
申请号：US10625307
申请日：2003-07-23
申请人： Julia Elizabeth Thompson , Tristan John Vaughan , Andrew James Williams , Jonathan Alexander Green , Ronald Henry Jackson , Louise Bacon , Kevin Stuart Johnson , Alison Jane Wilton , Philip Ronald Tempest , Raymond Paul Field , Steven Paul Ruddock , Gregory Paul Winter
发明人： Julia Elizabeth Thompson , Tristan John Vaughan , Andrew James Williams , Jonathan Alexander Green , Ronald Henry Jackson , Louise Bacon , Kevin Stuart Johnson , Alison Jane Wilton , Philip Ronald Tempest , Raymond Paul Field , Steven Paul Ruddock , Gregory Paul Winter
IPC分类号： A61K39/395 , C07K16/24
CPC分类号： C07K16/22 , A61K38/00 , C07K2317/21 , C07K2317/622
摘要： Specific binding members comprising human antibody antigen binding domains specific for human transforming growth factor beta (TGFβ) bind specifically isoforms TGFβ2 and TGFβ1 or both, preferentially compared with TGFβ3. Specific binding members may be isolated and utilized in the treatment of disease, particularly fibrotic disease and also immune/inflammatory diseases. Therapeutic utility is demonstrated using in vitro and in vivo models. Full sequence and binding information is provided, including epitope sequence information for particularly advantageous specific binding member which binds the active form of TGFβ2, neutralizing its activity, but does not bind the latent member.
摘要翻译：包含对人转化生长因子β（TGFbeta）特异性的人抗体结合结构域的特异性结合成员特异性结合TGFβ2和TGFbeta1或两者，优先与TGFbeta3相比较。特异性结合成员可以被分离并用于治疗疾病，特别是纤维化疾病以及免疫/炎性疾病。使用体外和体内模型证明治疗效用。提供了完整的序列和结合信息，包括用于结合TGFβ2活性形式的特别有利的特异性结合成员的表位序列信息，中和其活性但不结合潜伏成员。

10. 发明授权

US08715961B2 Methods of obtaining a specific binding member that binds eotaxin 有权
标题翻译：获得结合嗜酸性粒细胞趋化因子的特异性结合成员的方法
公开(公告)号：US08715961B2
公开(公告)日：2014-05-06
申请号：US13277132
申请日：2011-10-19
申请人： Tristan John Vaughan , Alison Jane Wilton , Stephen Smith , Sarah Helen Main
发明人： Tristan John Vaughan , Alison Jane Wilton , Stephen Smith , Sarah Helen Main
IPC分类号： C12P21/06 , C12P21/04 , C12N15/63 , C07K16/00
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2319/00 , C12P21/00
摘要： Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralize eotaxin-1 activity. The antibodies VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT 213. One or more complementary determining regions (CDRs) of the CAT-212-213 VH and/or VL domains, especially VH CRD3 in other antibody framework regions. Compositions containing specific binding members, and their use in methods of inhibiting or neutralizing eotaxin, including methods of treatment of the human or animal body by therapy.
摘要翻译：针对嗜酸细胞活化趋化因子-1的特异性结合成员，特别是针对人类嗜酸细胞活化趋化因子-1的人抗体和抗体片段，特别是中和嗜酸性粒细胞趋化因子-1活性的那些。本文称为CAT-212和本文称为CAT 213的IgG4抗体的scFv片段的抗体VH和/或VL结构域.CAT-212-213VH和/或VL结构域的一个或多个互补决定区（CDR）特别是VH CRD3在其他抗体框架区域。含有特异性结合成员的组合物及其在抑制或中和嗜酸性粒细胞趋化因子的方法中的用途，包括通过治疗来治疗人或动物体的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式